Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Secretory Leukocyte Protease Inhibitor and Helicobacter pylori in the Gastrointestinal Tract of HIV-infected Persons: A Review
The Internet Journal of Gastroenterology, 07/02/09
Chattopadhyay A et al. - Prevalence/incidence of Helicobater pylori (Hp) is reduced in HIV/AIDS. HIV-infection may alter the prevalence/incidence or pathology of Helicobacter pylori (Hp) infection. Secretory leukocyte protease inhibitor (SLPI) is an important broad spectrum innate immunity component that has anti-bacterial and HIV-1 inhibitory activity in different mucosal secretions and possibly in the local mucosal tissue milieu.
Today in GI Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Zinc and micronutrient combinations to combat gastrointestinal inflammation
Current Opinion in Clinical Nutrition & Metabolic Care, 10/23/09
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea
Therapeutics and Clinical Risk Management, 10/21/09
Methane and the Gastrointestinal Tract
Digestive Diseases and Sciences, 10/22/09
Sponsor
Article Search
Sponsor


See Latest Articles


